

# Florbetaben for Imaging of Vascular Amyloid

NCT06091319

---

**Status** RECRUITING  
**Sponsor** Ottawa Heart Institute Research Corporation  
**Enrollment** 30 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
- stable symptoms and hemodynamics;
- age  $\geq$  18 years;
- given informed consent.

### Exclusion (11)

- a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
- severe LV dysfunction ( $EF < 30\%$ );
- severe valve disease requiring intervention;
- decompensated heart failure;
- pregnancy (all women of child bearing potential will have a negative BHCG test;
- ... and 6 more (see full listing online)

## Locations (1 total)

---

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

---

<https://clinicaltrials.gov/study/NCT06091319>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).